Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 6Carcinoma, Intraductal, Noninfiltrating 2Breast Carcinoma In Situ 2Triple Negative Breast Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × Mastectomy, Segmental × Clear all
NCT00238615 2015-05-12

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Stanford University

Phase 2 Terminated
13 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡